Human Pathology
Volume 41, Issue 1 , Pages 70-78 , January 2010

Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer

  • Parham Minoo, MD, PhD

      Affiliations

    • Department of Pathology, University of California San Diego, San Diego, CA 92093, USA
    • ,
  • Kristi Baker, PhD

      Affiliations

    • Department of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115, USA
    • ,
  • Daniel Baumhoer, MD

      Affiliations

    • Institute of Pathology, University Hospital of Basel, 4031 Basel, Switzerland
    • ,
  • Luigi Terracciano, MD

      Affiliations

    • Institute of Pathology, University Hospital of Basel, 4031 Basel, Switzerland
    • ,
  • Alessandro Lugli, MD

      Affiliations

    • Institute of Pathology, University Hospital of Basel, 4031 Basel, Switzerland
    • ,
  • Inti Zlobec, PhD

      Affiliations

    • Institute of Pathology, University Hospital of Basel, 4031 Basel, Switzerland
    • Corresponding Author InformationCorresponding author.

Received 16 February 2009 ,Revised 17 April 2009 ,Accepted 7 May 2009.

References 

  1. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol. 2000;12:621–628
  2. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev. 2001;21:146–170
  3. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–943
  4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  5. Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem. 2006;281:17758–17767
  6. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25–40
  7. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem. 2000;275:10228–10234
  8. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–222
  9. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13–39
  10. Fernebro E, Madsen RR, Ferno M, et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer. 2001;37:486–491
  11. Konno H, Abe J, Kaneko T, et al. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res. 2001;92:516–523
  12. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis. 2002;19:527–534
  13. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol. 2003;82:184–193
  14. Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut. 1998;43:798–805
  15. Yang JL, Seetoo D, Wang Y, et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer. 2000;89:431–439
  16. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer. 1999;80:1884–1891
  17. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996;61:430–443
  18. Shiou SR, Datta PK, Dhawan P, et al. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J Biol Chem. 2006;281:33971–33981
  19. Hiendlmeyer E, Regus S, Wassermann S, et al. Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res. 2004;64:1209–1214
  20. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303–1306
  21. Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129:415–421
  22. Zlobec I, Lugli A, Baker K, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol. 2007;212:260–268
  23. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 2008;14:5649–5655
  24. Sieber OM, Heinimann K, Tomlinson IP. Genomic instability—the engine of tumorigenesis. Nat Rev Cancer. 2003;3:701–708
  25. Hlubek F, Jung A, Kotzor N, Kirchner T, Brabletz T. Expression of the invasion factor laminin gamma2 in colorectal carcinomas is regulated by beta-catenin. Cancer Res. 2001;61:8089–8093
  26. Jass JR, Barker M, Fraser L, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol. 2003;56:69–73
  27. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003;201:528–534
  28. Wong NA, Pignatelli M. Beta-catenin—a linchpin in colorectal carcinogenesis. Am J Pathol. 2002;160:389–401
  29. Lugli A, Zlobec I, Minoo P, et al. Prognostic significance of the Wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology. 2007;50:453–464
  30. Zlobec I, Minoo P, Baumhoer D, et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer. 2008;112:495–502
  31. Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007;50:151–162
  32. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem. 2001;276:3983–3990
  33. Riisbro R, Christensen IJ, Nielsen HJ, Brunner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers. 2005;20:93–102
  34. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999;91:869–874
  35. Obermeyer K, Krueger S, Peters B, Falkenberg B, Roessner A, Rocken C. The expression of low density lipoprotein receptor-related protein in colorectal carcinoma. Oncol Rep. 2007;17:361–367

PII: S0046-8177(09)00234-2

doi: 10.1016/j.humpath.2009.05.013

Human Pathology
Volume 41, Issue 1 , Pages 70-78 , January 2010

Article Tools

* Image Usage & Resolution